STUDIES ABOUT CURRENT MEASURES (PCR TESTS, MASKS, VACCINE,...)

​

VACCINE

​

•  Vaccine Guide Page about every topic related to vaccines: studies, ingredients, working of the vaccine,…

• Vaccine resources

• What Ingredients are in the COVID-19 Vaccine

• Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

• Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

• SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition

• Informed consent disclosure to vaccine trial subjects of risk of COVID-19 vaccines worsening clinical disease

• Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

• SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms

• Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies

• Two Different Antibody-Dependent Enhancement (ADE) Risks for SARS-CoV-2 Antibodies

• The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses

• Vaccines for preventing influenza in healthy adults

• Thromboembolism and the Oxford–AstraZeneca COVID-19 vaccine: side-effect or coincidence?

• COVID-19 vaccine efficacy and effectiveness—the elephant (not) in the room

• Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients

• Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older

• Pfizer-BioNTech COVID-19 BNT162b2 Vaccine Effectiveness Study

• Pfizer-BioNTech COVID-19 vaccine study 2

• The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine

• Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)

• Outcome Reporting Bias in COVID-19 mRNA Vaccine Clinical Trials

• Vaccine BNT162b2 – Conditions of authorisation under Regulation: This temporary Authorisation under Regulation 174 permits the supply of identified COVID-19 mRNA Vaccine BNT162b2 batches, based on the safety, quality and efficacy data submitted by Pfizer/BioNTech to MHRA

• Biodistribution of Pfizer Covid-19 Vaccine

• Pfizer CUMULATIVE ANALYSIS OF POST-AUTHORIZATION ADVERSE EVENT REPORTS OF PF-07302048 (BNT162B2)

• Protection of previous SARS-CoV-2 infection is similar to that of  BNT162b2 vaccine protection:  A 3-month nationwide experience from Israel

• Infection-enhancing anti-SARS-CoV-2 antibodies recognize both the original Wuhan/D614G strain and Delta variants. A potential risk for mass vaccination?

• Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

• Increases in COVID-19 are unrelated to levels of vaccination across 68 countries and 2947 counties in the United States

• Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections

• Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

• Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains

• European Medicines Agency: Comirnaty vaccine

• European Medicines Agency: Pharmacovigilance Plan of the EU Regulatory Network for
  COVID-19 Vaccines

• EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU

• UK Department of Health and Social Care: Summary of the Public Assessment Report for COVID-19 Vaccine Pfizer/BioNTech

• UK department of Health and Social Care: Public Assessment Report Authorisation for Temporary Supply COVID-19 mRNA Vaccine BNT162b2 (BNT162b2 RNA)

• Peter Doshi: Clarification: Pfizer and Moderna’s “95% effective” vaccines—we need more details and the raw data

• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

• FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine

• UK Medicines & Healthcare products Regulatory Agency: Summary of Product Characteristics for Spikevax

• CDC: Interim Considerations: Preparing for the Potential Management of Anaphylaxis after COVID-19 Vaccination

• FDA: Immunogenicity Testing of Therapeutic Protein Products —Developing and Validating Assays for Anti-Drug Antibody Detection

• FDA: Development and Licensure of Vaccines to Prevent COVID-19 - Guidance for Industry

• Moderna COVID-19 Vaccine VRBPAC Briefing Document

• Updates on the Status of Vitamin D as a Risk Factor for Respiratory Distress Syndrome

• Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19

• Low plasma 25(OH) vitamin D level is associated with increased risk of COVID-19 infection

• THE VACCINE DEATH REPORT from stopworldcontrol.com

• Pfizer A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

• FACT SHEET FOR HEALTHCARE PROVIDERS ADMINISTERING JANSSEN VACCINE

• FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19

• Janssen Vaccine Technology

• Janssen Vaccine SUMMARY OF PRODUCT CHARACTERISTICS (EMA)

• Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions

• Hypersensitivity reaction to human papillomavirus vaccine due to polysorbate 80

• SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

• The tangled history of mRNA vaccines

• SARS-CoV-2 mRNA vaccines induce a robust germinal centre reaction in humans

• Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine 

• Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

• Maintaining Safety with SARS-CoV-2 Vaccines 

• Severe allergic reactions to the COVID-19 vaccine - statement and practical consequences 

• EMA: COVID-19 vaccines: update on ongoing evaluation of myocarditis and pericarditis 

• Vaccinology: time to change the paradigm?

• Direct and Indirect Effectiveness of mRNA Vaccination against Severe Acute Respiratory Syndrome Coronavirus 2 in Long-Term Care Facilities, Spain

• Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

• New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications

• Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

• Imperfect Vaccination Can Enhance the Transmission of Highly Virulent Pathogens 

• ​

​

​

MASKS

​

• book Dr. Vernon Coleman - Proof that face masks do more harm than good

• Guantanamo torture: surgical masks make breathing more difficult

• Physical interventions to interrupt or reduce the spread of respiratory viruses 

• Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-2 Infection in Danish Mask Wearers

• Surgical masks as source of bacterial contamination during operative procedures

• Experimental Assessment of Carbon Dioxide Content in Inhaled Air With or Without Face Masks in Healthy Children

• A cluster randomised trial of cloth masks compared with medical masks in healthcare workers

• The physiological impact of wearing an N95 mask during hemodialysis as a precaution against SARS in patients with end-stage renal disease

• The Physiological Impact of N95 Masks on Medical Staff

• Is a Mask That Covers the Mouth and Nose Free from Undesirable Side Effects in Everyday Use and Free of Potential Hazards?

• Article: Are Face Masks Effective? The Evidence

• CDC: Nonpharmaceutical Measures for Pandemic Influenza in Nonhealthcare Settings Personal Protective and Environmental Measures

• WHO: Non-pharmaceutical public health measures for mitigating the risk and impact of epidemic and pandemic influenza

• Facemask against viral respiratory infections among Hajj pilgrims: A challenging cluster-randomized trial

• Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention

• Mask mandate and use efficacy for COVID-19 containment in US States

• An investigation into the leaching of micro and nano particles and chemical pollutants from disposable face masks

• Titanium dioxide in our everyday life; is it safe? 

• Face masks and nanotechnology: Keep the blue side up 

• Titanium dioxide nanoparticles - biological effects 

• Titanium Dioxide hazardous substance fact sheet  

• Nanoplastics and other harmful pollutants found within disposable face masks 

• COVID-19: Performance study of microplastic inhalation risk posed by wearing masks 

• Titanium dioxide particles frequently present in face masks intended for general use require regulatory control 

​

PCR     
 

• External peer review of the RTPCR test to detect SARS-CoV-2 reveals 10 major scientific flaws at the molecular and methodological level: consequences for false positive results.

• CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel - Instructions for Use

• Post-lockdown SARS-CoV-2 nucleic acid screening in nearly ten million residents of Wuhan, China

• COVID19 PCR Tests are Scientifically Meaningless

• Interim Laboratory Biosafety Guidelines for Handling and Processing Specimens Associated with Coronavirus Disease 2019